An open-label study of escitalopram (Lexapro®) for the treatment of ‘Depression of Alzheimer's disease’ (dAD)

Abstract Background Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8‐week, open‐label treatment study. Conclusion Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population. Copyright © 2006 John Wiley & Sons, Ltd.